[go: up one dir, main page]

AR086839A1 - Derivados de piridin-2-ona con actividad inhibitoria de ezh2 - Google Patents

Derivados de piridin-2-ona con actividad inhibitoria de ezh2

Info

Publication number
AR086839A1
AR086839A1 ARP120101289A ARP120101289A AR086839A1 AR 086839 A1 AR086839 A1 AR 086839A1 AR P120101289 A ARP120101289 A AR P120101289A AR P120101289 A ARP120101289 A AR P120101289A AR 086839 A1 AR086839 A1 AR 086839A1
Authority
AR
Argentina
Prior art keywords
alkyl
halo
cyano
cycloalkyl
amino
Prior art date
Application number
ARP120101289A
Other languages
English (en)
Inventor
Heike Keilhack
C-Duncan Kenneth W Klaus
Kevin Wayne Kuntz
Natalie Warholic
Richard Chesworth
Original Assignee
Epizyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epizyme Inc filed Critical Epizyme Inc
Publication of AR086839A1 publication Critical patent/AR086839A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Derivados de 2-piridona, una composición farmacéutica que los comprende y su uso en el tratamiento del cáncer.Reivindicación 1: Un compuesto de la fórmula (1) o una de sus sales farmacéuticamente aceptables, en donde X1 es N o CR11; X2 es N o CR13; X3 es N o C y cuando X3 es N, R6 está ausente; Z es NR7R8, OR7, S(O)aR7 o CR7R8R14, en donde a es 0, 1 ó 2; cada uno de R1, R5, R9 y R10, de modo independiente, es H o alquilo C1-6 opcionalmente sustituido con uno o varios sustituyentes seleccionados del grupo que consiste en halo, hidroxilo, COOH, C(O)O-alquilo C1-6, ciano, alcoxilo C1-6, amino, mono-alquil C1-6-amino, di-alquil C1-6-amino, cicloalquilo C3-8, arilo C6-10, heterocicloalquilo de 4 a 12 miembros y heteroarilo de 5 ó 6 miembros; cada uno de R2, R3 y R4, de modo independiente, es -Q1-T1, en donde Q1 es un enlace o ligador de alquilo C1-3 opcionalmente sustituido con halo, ciano, hidroxilo o alcoxi C1-6 y T1 es H, halo, hidroxilo, COOH, ciano, azido o RS1, en donde RS1 es alquilo C1-3, alquenilo C2-6, alquinilo C2-6, alcoxilo C1-6, C(O)O-alquilo C1-6, cicloalquilo C3-8, arilo C6-10, amino, mono-alquil C1-6-amino, di-alquil C1-6-amino, heterocicloalquilo de 4 a 12 miembros o heteroarilo de 5 ó 6 miembros y RS1 está opcionalmente sustituido con uno o varios sustituyentes seleccionados del grupo que consiste en halo, hidroxilo, oxo, COOH, C(O)O-alquilo C1-6, ciano, alcoxilo C1-6, amino, mono-alquil C1-6-amino, di-alquil C1-6-amino, cicloalquilo C3-8, arilo C6-10, heterocicloalquilo de 4 a 12 miembros y heteroarilo de 5 ó 6 miembros; R6 es H, halo, ciano, azido, ORa, -NRaRb, -C(O)Ra, -C(O)ORa, -C(O)NRaRb, -NRbC(O)Ra, -S(O)bRa, -S(O)bNRaRb o RS2, en donde RS2 es alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-8 o heterocicloalquilo de 4 a 12 miembros, b es 0, 1 ó 2, cada uno de Ra y Rb, de modo independiente es H o RS3 y RS3 es alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-8, arilo C6-10, heterocicloalquilo de 4 a 12 miembros o heteroarilo de 5 ó 6 miembros; o Ra y Rb, junto con el átomo de N al que están unidos, forman un anillo heterocicloalquilo de 4 a 12 miembros que tiene 0 ó 1 heteroátomos adicionales; y cada uno de RS2, RS3 y el anillo heterocicloalquilo de 4 a 12 miembros formado por Ra y Rb, está opcionalmente sustituido con uno o varios -Q2-T2, en donde Q2 es un enlace o ligador de alquilo C1-3 cada uno opcionalmente sustituido con halo, ciano, hidroxilo o alcoxi C1-6 y T2 es H, halo, ciano, -ORc, -NRcRd, -C(O)Rc, -C(O)ORc, -C(O)NRcRd, -NRdC(O)Rc, NRdC(O)ORc, -S(O)2Rc, -S(O)2NRcRd o RS4, en donde cada uno de Rc y Rd, de modo independiente es H o RS5, cada uno de RS4 y RS5, de modo independiente, es alquilo C1-6, cicloalquilo C3-8, arilo C6-10, heterocicloalquilo de 4 a 12 miembros o heteroarilo de 5 ó 6 miembros o Rc y Rd, junto con el átomo de N al que están unidos, forman un anillo heterocicloalquilo de 4 a 12 miembros que tiene 0 ó 1 heteroátomos adicionales y cada uno de RS4, RS5 y el anillo heterocicloalquilo de 4 a 12 miembros formado por Rc y Rd, está opcionalmente sustituido con uno o varios -Q3-T3, en donde Q3 es un enlace o ligador de alquilo C1-3 cada uno opcionalmente sustituido con halo, ciano, hidroxilo o alcoxi C1-6 y T3 está seleccionado del grupo que consiste en halo, ciano, alquilo C1-6, cicloalquilo C3-8, arilo C6-10, heterocicloalquilo de 4 a 12 miembros, heteroarilo de 5 ó 6 miembros, ORe, COORe, -S(O)2Re, -NReRf y -C(O)NReRf, siendo cada uno de Re y Rf de modo independiente H o alquilo C1-6 o -Q3-T3 es oxo; o -Q2-T2 es oxo; R7 es -Q4-T4, en donde Q4 es un enlace, ligador de alquilo C1-4 o ligador de alquenilo C2-4, cada ligador opcionalmente sustituido con halo, ciano, hidroxilo o alcoxi C1-6 y T4 es H, halo, ciano, NRgRh, -ORg, -C(O)Rg, -C(O)ORg, -C(O)NRgRh, -C(O)NRgORh, -NRgC(O)Rh, S(O)2Rg o RS6, en donde cada uno de Rg y Rh, de modo independiente es H o RS7, cada uno de RS6 y RS7, de modo independiente es alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-8, arilo C6-10, heterocicloalquilo de 4 a 14 miembros o heteroarilo de 5 ó 6 miembros y cada uno de RS6 y RS7 está opcionalmente sustituido con uno o varios -Q5-T5, en donde Q5 es un enlace, C(O), C(O)NRk, NRkC(O), S(O)2 o ligador de alquilo C1-3, siendo Rk H o alquilo C1-6 y T5 es H, halo, alquilo C1-6, hidroxilo, ciano, alcoxilo C1-6, amino, mono-alquil C1-6-amino, di-alquil C1-6-amino, cicloalquilo C3-8, arilo C6-10, heterocicloalquilo de 4 a 12 miembros, heteroarilo de 5 ó 6 miembros o S(O)qRq, en donde q es 0, 1 ó 2 y Rq es alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-8, arilo C6-10, heterocicloalquilo de 4 a 12 miembros o heteroarilo de 5 ó 6 miembros y T5 está opcionalmente sustituido con uno o varios sustituyentes seleccionados del grupo que consiste en halo, alquilo C1-6, hidroxilo, ciano, alcoxilo C1-6, amino, mono-alquil C1-6-amino, di-alquil C1-6-amino, cicloalquilo C3-8, arilo C6-10, heterocicloalquilo de 4 a 12 miembros y heteroarilo de 5 ó 6 miembros excepto cuando T5 es H, halo, hidroxilo o ciano; o -Q5-T5 es oxo; cada uno de R8, R11, R12 y R13, de modo independiente, es H, halo, hidroxilo, COOH, ciano, RS8, ORS8 o COORS8, en donde RS8 es alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-8, heterocicloalquilo de 4 a 12 miembros, amino, mono-alquil C1-6-amino o di-alquil C1-6-amino y RS8 está opcionalmente sustituido con uno o varios sustituyentes seleccionados del grupo que consiste en halo, hidroxilo, COOH, C(O)O-alquilo C1-6, ciano, alcoxilo C1-6, amino, mono-alquil C1-6-amino y di-alquil C1-6-amino; o R7 y R8, junto con el átomo de N al que están unidos, forman un anillo heterocicloalquilo de 4 a 12 miembros que tiene 0 a 2 heteroátomos adicionales o R7 y R8, junto con el átomo de C al que están unidos, forman cicloalquilo C3-8 o un anillo heterocicloalquilo de 4 a 12 miembros que tiene 1 a 3 heteroátomos y cada uno del anillo heterocicloalquilo de 4 a 12 miembros o cicloalquilo C3-8 formado R7 y R8 está opcionalmente sustituido con uno o varios -Q6-T6, en donde Q6 es un enlace, C(O), C(O)NRm, NRmC(O), S(O)2 o ligador de alquilo C1-3, siendo Rm H o alquilo C1-6 y T6 es H, halo, alquilo C1-6, hidroxilo, ciano, alcoxilo C1-6, amino, mono-alquil C1-6-amino, di-alquil C1-6- amino, cicloalquilo C3-8, arilo C6-10, heterocicloalquilo de 4 a 12 miembros, heteroarilo de 5 ó 6 miembros o S(O)pRp, en donde p es 0, 1 ó 2 y Rp es alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-8, arilo C6-10, heterocicloalquilo de 4 a 12 miembros o heteroarilo de 5 ó 6 miembros y T6 está opcionalmente sustituido con uno o varios sustituyentes seleccionados del grupo que consiste en halo, alquilo C1-6, hidroxilo, ciano, alcoxilo C1-6, amino, mono-alquil C1-6-amino, di-alquil C1-6-amino, cicloalquilo C3-8, arilo C6-10, heterocicloalquilo de 4 a 12 miembros y heteroarilo de 5 ó 6 miembros excepto cuando T6 es H, halo, hidroxilo o ciano; o -Q6-T6 es oxo; y R14 está ausente, H o alquilo C1-6 opcionalmente sustituido con uno o varios sustituyentes seleccionados del grupo que consiste en halo, hidroxilo, COOH, C(O)O-alquilo C1-6, ciano, alcoxilo C1-6, amino, mono-alquil C1-6-amino, di-alquil C1-6-amino, cicloalquilo C3-8, arilo C6-10, heterocicloalquilo de 4 a 12 miembros y heteroarilo de 5 ó 6 miembros; siempre que el compuesto no sea N-(5-(((4,6-dimetil-2-oxo-1,2-dihidropiridin-3-il)metil)carbamoil)-2-metilfenil)furan-2-carboxamida, N,N’-(5-(((4,6-dimetil-2-oxo-1,2-dihidropiridin-3-il)metil)carbamoil)-1,3-fenilen)diacetamida, N-((4,6-dimetil-2-oxo-1,2-dihidropiridin-3-il)metil)-3-pivalamidobenzamida, 3-(3,4-dihidro-2H-benzo[b][1,4]dioxepin-7-sulfonamido)-N-((4,6-dimetil-2-oxo-1,2-dihidropiridin-3-il)metil)benzamida, N-((4,6-dimetil-2-oxo-1,2-dihidropiridin-3-il)metil)-3,5-dimetoxibenzamida, N-((4,6-dimetil-2-oxo-1,2-dihidropiridin-3-il)metil)-3,4,5-trimetoxibenzamida, 3-alil-N-((4,6-dimetil-2-oxo-1,2-dihidropiridin-3-il)metil)-4,5-dimetoxibenzamida, 4-(2-amino-2-oxoetoxi)-3-cloro-N-((4,6-dimetil-2-oxo-1,2-dihidropiridin-3-il)metil)-5-metoxibenzamida, 3-cloro-N-((4,6-dimetil-2-oxo-1,2-dihidropiridin-3-il)metil)-4-hidroxi-5-metoxibenzamida, o 3-bromo-N-((4,6-dimetil-2-oxo-1,2-dihidropiridin-3-il)metil)-5-metoxi-4-propoxibenzamida.
ARP120101289A 2011-04-13 2012-04-13 Derivados de piridin-2-ona con actividad inhibitoria de ezh2 AR086839A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161474825P 2011-04-13 2011-04-13
US201161505676P 2011-07-08 2011-07-08

Publications (1)

Publication Number Publication Date
AR086839A1 true AR086839A1 (es) 2014-01-29

Family

ID=46000399

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120101289A AR086839A1 (es) 2011-04-13 2012-04-13 Derivados de piridin-2-ona con actividad inhibitoria de ezh2

Country Status (20)

Country Link
US (2) US9376422B2 (es)
EP (3) EP3470396A1 (es)
JP (1) JP2014513084A (es)
KR (1) KR101975613B1 (es)
CN (1) CN104066718B (es)
AR (1) AR086839A1 (es)
AU (2) AU2012242604B2 (es)
BR (1) BR112013026308B1 (es)
CA (1) CA2832846C (es)
DK (1) DK2697198T3 (es)
ES (1) ES2590489T3 (es)
HK (1) HK1202534A1 (es)
HU (1) HUE030722T2 (es)
IL (1) IL228746B (es)
MX (1) MX344530B (es)
PL (1) PL2697198T3 (es)
PT (1) PT2697198T (es)
RU (2) RU2017126990A (es)
TW (2) TW201733984A (es)
WO (1) WO2012142513A1 (es)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130102477A1 (en) 2010-06-23 2013-04-25 Ryan D. Morin Biomarkers for non-hodgkin lymphomas and uses thereof
BR112013005806B1 (pt) 2010-09-10 2022-05-10 Epizyme, Inc Métodos para detectar se um indivíduo é um candidato para o tratamento com ou responsivo a um inibidor de ezh2 e usos terapêuticos do dito inibidor de ezh2
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
WO2013075084A1 (en) * 2011-11-18 2013-05-23 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
CA2862289C (en) 2012-02-10 2019-11-26 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
IL308807B2 (en) 2012-04-13 2025-08-01 Epizyme Inc Combination therapy for treating cancer
PL2836491T3 (pl) 2012-04-13 2017-08-31 Epizyme, Inc. Postać soli inhibitora ludzkiej metylotransferazy histonowej EZH2
US9562041B2 (en) 2012-05-16 2017-02-07 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
CA2884848C (en) * 2012-09-28 2017-08-22 Pfizer Inc. Benzamide and heterobenzamide compounds
IL308613A (en) * 2012-10-15 2024-01-01 Epizyme Inc Cancer treatment methods
US9006242B2 (en) 2012-10-15 2015-04-14 Epizyme, Inc. Substituted benzene compounds
TWI494424B (zh) * 2012-11-20 2015-08-01 Dow Global Technologies Llc 可蒸餾燃料標記物
RU2015127822A (ru) * 2012-12-13 2017-01-16 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Ингибиторы энхансера гомолога 2 белка zeste
EP2935264B1 (en) 2012-12-21 2017-10-18 Epizyme, Inc. 1,4-pyridone bicyclic heteroaryl compounds
UA111305C2 (uk) * 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
EP2935214B1 (en) 2012-12-21 2019-02-20 Epizyme, Inc. 1,4-pyridone compounds
BR112015022785A2 (pt) 2013-03-14 2017-07-18 Epizyme Inc composto; composição farmacêutica; kit ou artigo farmacêutico embalado; método de inibição de uma arginina metil transferase (rmt); método de modulação da expressão genética; método de modulação da transcrição; e método de tratamento de um distúrbio mediado por rmt
EP2970220A2 (en) 2013-03-14 2016-01-20 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US9447079B2 (en) 2013-03-14 2016-09-20 Epizyme, Inc. PRMT1 inhibitors and uses thereof
US9023883B2 (en) 2013-03-14 2015-05-05 Epizyme, Inc. PRMT1 inhibitors and uses thereof
US9120757B2 (en) 2013-03-14 2015-09-01 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
CA2903264A1 (en) 2013-03-14 2014-11-06 Epizyme, Inc. Pyrazole derivatives as arginine methyltransferase inhibitors and uses thereof
WO2014153208A1 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US9133189B2 (en) 2013-03-14 2015-09-15 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US9365527B2 (en) 2013-03-14 2016-06-14 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US20160039767A1 (en) 2013-03-14 2016-02-11 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
WO2014144326A1 (en) 2013-03-15 2014-09-18 G1 Therapeutics, Inc. Transient protection of normal cells during chemotherapy
US9745305B2 (en) 2013-03-15 2017-08-29 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
EP2970281A4 (en) * 2013-03-15 2016-08-03 Epizyme Inc SUBSTITUTED BENZOL COMPOUNDS
EA030196B1 (ru) * 2013-04-30 2018-07-31 Глэксосмитклайн Интеллекчуал Проперти (No.2) Лимитед Ингибиторы энхансера zeste гомолога 2
US9556157B2 (en) 2013-07-10 2017-01-31 Glaxosmithkline Intellectual Property (No.2) Limited Enhancer of zeste homolog 2 inhibitors
US9624205B2 (en) 2013-07-19 2017-04-18 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
US10150764B2 (en) 2013-07-19 2018-12-11 Epizyme, Inc. Substituted benzene compounds
EP3033334A1 (en) 2013-08-15 2016-06-22 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
EA038869B1 (ru) 2013-10-16 2021-10-29 Эпизим, Инк. Кристаллические формы гидрохлорида n-((4,6-диметил-2-оксо-1,2-дигидропиридин-3-ил)метил)-5-(этил(тетрагидро-2h-пиран-4-ил)амино)-4-метил-4'-(морфолинометил)-[1,1'-бифенил]-3-карбоксамида, фармацевтические композиции на их основе и способы их применения
US9738630B2 (en) 2013-11-19 2017-08-22 Bristol-Myers Squibb Company Inhibitors of lysine methyl transferase
WO2015077194A1 (en) * 2013-11-22 2015-05-28 Bristol-Myers Squibb Company Inhibitors of lysine methyl transferase
CN116019921A (zh) 2013-12-06 2023-04-28 Epizyme股份有限公司 用于治疗癌症的组合疗法
LT3157527T (lt) 2014-06-17 2023-07-25 Epizyme, Inc. Ezh2 inhibitoriai, skirti limfomos gydymui
GEAP201814347A (en) * 2014-06-17 2018-08-10 Pfizer Substituted dihydroisoquinoline compounds
WO2015200650A1 (en) 2014-06-25 2015-12-30 Epizyme, Inc. Substituted benzene and 6,5-fused bicyclic heteroaryl compounds
CA2963149A1 (en) 2014-10-16 2016-04-21 Epizyme, Inc. Method for treating cancer
CA2965729A1 (en) * 2014-10-28 2016-05-06 Glaxosmithkline Intellectual Property (No.2) Limited Enhancer of zeste homolog 2 inhibitors
MX383484B (es) 2014-11-17 2025-03-11 Epizyme Inc Método para tratar el cáncer.
AR102767A1 (es) 2014-12-05 2017-03-22 Lilly Co Eli Inhibidores de ezh2
US20180271857A1 (en) 2014-12-23 2018-09-27 University Of Copenhagen Treatment of cancer by inhibiting ezh2 activity
SG10201902664RA (en) 2015-04-20 2019-04-29 Epizyme Inc Combination therapy for treating cancer
US20180133211A1 (en) * 2015-05-19 2018-05-17 Mayo Foundation For Medical Education And Research Methods and materials for promoting bone formation
MX387885B (es) 2015-06-10 2025-03-19 Epizyme Inc Inhibidores de ezh2 para tratar linfomas.
WO2017035234A1 (en) 2015-08-24 2017-03-02 Epizyme, Inc. Method for treating cancer
TW201718598A (zh) 2015-08-27 2017-06-01 美國禮來大藥廠 Ｅｚｈ２抑制劑
WO2017040190A1 (en) 2015-08-28 2017-03-09 Constellation Pharmaceuticals, Inc. Crystalline forms of (r)-n-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1h-indole-3-carboxamide
EP3378859B1 (en) 2015-11-19 2019-10-30 Jiangsu Hengrui Medicine Co., Ltd. Benzofuran derivative, preparation method thereof and use thereof in medicine
TWI773657B (zh) 2015-12-18 2022-08-11 美商亞德利克斯公司 作爲非全身ｔｇｒ５促效劑之經取代之4-苯基吡啶化合物
US12084472B2 (en) 2015-12-18 2024-09-10 Ardelyx, Inc. Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists
JP2019503391A (ja) 2016-01-29 2019-02-07 エピザイム，インコーポレイティド 癌を処置するための併用療法
CN109311859B (zh) * 2016-04-14 2022-01-21 广州嘉越医药科技有限公司 用于治疗纤维化和炎性疾病的含杂原子环丁烷取代基的吡啶酮衍生物
WO2017210395A1 (en) 2016-06-01 2017-12-07 Epizyme, Inc. Use of ezh2 inhibitors for treating cancer
EP3471830A4 (en) 2016-06-17 2020-02-26 Epizyme Inc EZH2 INHIBITORS TO TREAT CANCER
US10457640B2 (en) 2016-10-19 2019-10-29 Constellation Pharmaceuticals, Inc. Synthesis of inhibitors of EZH2
CN108314677B (zh) 2017-01-17 2020-06-30 安徽中科拓苒药物科学研究有限公司 一种ezh2抑制剂及其用途
US11214561B2 (en) 2017-01-25 2022-01-04 Ancureall Pharmaceutical (Shanghai) Co., Ltd. Histone methyltransferase EZH2 inhibitor, preparation method and pharmaceutical use thereof
US11395821B2 (en) 2017-01-30 2022-07-26 G1 Therapeutics, Inc. Treatment of EGFR-driven cancer with fewer side effects
US10266542B2 (en) 2017-03-15 2019-04-23 Mirati Therapeutics, Inc. EZH2 inhibitors
WO2018183885A1 (en) 2017-03-31 2018-10-04 Epizyme, Inc. Combination therapy for treating cancer
EP3612181A4 (en) * 2017-04-21 2021-01-06 Epizyme, Inc. Combination therapies with ehmt2 inhibitors
TWI772424B (zh) 2017-05-18 2022-08-01 大陸商江蘇恆瑞醫藥股份有限公司 一種苯并呋喃類衍生物游離鹼的晶型及製備方法
US11602529B2 (en) 2017-06-02 2023-03-14 Epizyme, Inc. Use of EZH2 inhibitors for treating cancer
CN111093660A (zh) 2017-09-05 2020-05-01 Epizyme股份有限公司 用于治疗癌症的组合疗法
AU2018363467B2 (en) 2017-11-10 2023-09-07 Jiangsu Hengrui Medicine Co., Ltd. Method for preparing benzofuran derivative
JP7201400B2 (ja) 2017-11-14 2023-01-10 ファイザー・インク Ｅｚｈ２阻害剤組合せ療法
BR112020015583B1 (pt) 2018-01-31 2022-12-06 Mirati Therapeutics, Inc Composto, composição farmacêutica e seu uso para tratar câncer
EP3823671B1 (en) 2018-07-09 2024-02-07 Fondation Asile Des Aveugles Inhibition of prc2 subunits to treat eye disorders
CA3106589A1 (en) 2018-07-27 2020-01-30 Suzhou Sinovent Pharma Co., Ltd. Polysubstituted benzene compound and preparation method and use thereof
MX2021007536A (es) 2018-12-21 2021-09-23 Les Laboratoires Servier Sas Formas de sal y cristalinas de un compuesto organico y composiciones farmaceuticas del mismo.
US12473298B2 (en) 2019-03-25 2025-11-18 Shanghai Synergy Pharmaceutical Sciences Co., Ltd. Amide compounds, preparation method therefor, and use thereof in the medical field
WO2020219448A1 (en) 2019-04-22 2020-10-29 Mirati Therapeutics, Inc. Naphthyridine derivatives as prc2 inhibitors
EP3980422A1 (en) 2019-06-05 2022-04-13 Mirati Therapeutics, Inc. Imidazo[1,2-c]pyrimidine derivatives as prc2 inhibitors for treating cancer
GB201908453D0 (en) * 2019-06-12 2019-07-24 Enterprise Therapeutics Ltd Compounds for treating respiratory disease
JP2022545467A (ja) 2019-08-22 2022-10-27 ジュノー セラピューティクス インコーポレイテッド Ｔ細胞療法とｚｅｓｔｅホモログ２エンハンサー（ＥＺＨ２）阻害剤との併用療法および関連方法
CN113248481B (zh) * 2021-04-19 2023-03-24 中山大学 Ezh2共价不可逆抑制剂、制备方法及其用途
CN113292489B (zh) * 2021-06-16 2022-08-30 泓博智源(开原)药业有限公司 二氯代二烷基烟腈的制备方法
AU2023292893A1 (en) 2022-06-13 2025-01-02 Treeline Biosciences, Inc. Quinolone bcl6 bifunctional degraders
IL317217A (en) 2022-06-13 2025-01-01 Treeline Biosciences Inc BCL6 heterobifunctional 8,1-naphthyridin-2-one joints

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
JPH0733729A (ja) 1993-07-26 1995-02-03 Kirin Brewery Co Ltd Ｎ−シアノ−ｎ′−置換−アリールカルボキシイミダミド化合物の製造法
RU2128644C1 (ru) 1993-12-27 1999-04-10 Эйсай Ко., Лтд. Производные антраниловой кислоты или их фармакологически приемлемые соли, промежуточные продукты для их получения и лекарственный препарат на их основе
DE19516776A1 (de) 1995-05-10 1996-11-14 Boehringer Ingelheim Int Chromatin-Regulatorgene
US5741819A (en) 1995-06-07 1998-04-21 3-Dimensional Pharmaceuticals, Inc. Arylsulfonylaminobenzene derivatives and the use thereof as factor Xa inhibitors
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
JP3906935B2 (ja) 1995-12-18 2007-04-18 杏林製薬株式会社 Ｎ−置換ジオキソチアゾリジルベンズアミド誘導体及びその製造法
BR9914207A (pt) 1998-09-30 2001-07-03 Procter & Gamble Ceto-amidas 2-substituìdas
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
US6710058B2 (en) 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
DK1357111T3 (da) 2000-12-28 2009-11-02 Shionogi & Co 2-pyridonderivater med affinitet for cannabinoid type 2-receptor
US7700293B2 (en) 2001-08-02 2010-04-20 The Regents Of The University Of Michigan Expression profile of prostate cancer
US20050101590A1 (en) 2002-02-19 2005-05-12 Kiyoshi Yasui Antipruritics
TW200306155A (en) 2002-03-19 2003-11-16 Du Pont Benzamides and advantageous compositions thereof for use as fungicides
US7442685B2 (en) 2003-06-13 2008-10-28 The University Of North Carolina At Chapel Hill DOT1 histone methyltransferases as a target for identifying therapeutic agents for leukemia
TWI324926B (en) * 2004-04-23 2010-05-21 Bristol Myers Squibb Co Monocyclic heterocycles as kinase inhibitors
WO2005118796A2 (en) 2004-06-01 2005-12-15 The University Of North Carolina At Chapel Hill Reconstituted histone methyltransferase complex and methods of identifying modulators thereof
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
US7923219B2 (en) 2005-06-02 2011-04-12 The University Of North Carolina At Chapel Hill Ubiquitin E3 ligase
FR2889526B1 (fr) 2005-08-04 2012-02-17 Aventis Pharma Sa 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
EP1940821B1 (de) 2005-10-19 2013-03-20 Grünenthal GmbH Neue vanilloid-rezeptor liganden und ihre verwendung zur herstellung von arzneimitteln
WO2007050347A1 (en) 2005-10-21 2007-05-03 Merck & Co., Inc. Potassium channel inhibitors
EP1941060B1 (en) 2005-10-28 2012-02-29 The University of North Carolina At Chapel Hill Protein demethylases comprising a jmjc domain
WO2007070818A1 (en) 2005-12-14 2007-06-21 Bristol-Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
WO2007087015A1 (en) 2006-01-20 2007-08-02 The University Of North Carolina At Chapel Hill Diagnostic and therapeutic targets for leukemia
CN101443007A (zh) 2006-05-15 2009-05-27 Irm责任有限公司 Terephthalamate化合物和组合物及其作为hiv整合酶抑制剂的用途
CA2652634A1 (en) * 2006-05-18 2007-11-29 Amphora Discovery Corporation Certain substituted quinolones, compositions, and uses thereof
EP2086318A4 (en) 2006-10-10 2009-12-23 Burnham Inst Medical Research NEUROPROTECTIVE COMPOSITIONS AND CORRESPONDING METHODS
MX2009008531A (es) 2007-02-16 2009-08-26 Amgen Inc Cetonas de heterociclilo que contienen nitrogeno y su uso como inhibidores de c-met.
US8338437B2 (en) 2007-02-28 2012-12-25 Methylgene Inc. Amines as small molecule inhibitors
WO2008113006A1 (en) * 2007-03-14 2008-09-18 Xenon Pharmaceuticals Inc. Methods of using quinolinone compounds in treating sodium channel-mediated diseases or conditions
DE102007017884A1 (de) 2007-04-13 2008-10-16 Grünethal GmbH Neue Vanilloid-Rezeptor Liganden und ihre Verwendung zur Herstellung von Arzneimitteln
US20090012031A1 (en) 2007-07-03 2009-01-08 The Regents Of The University Of Michigan EZH2 Cancer Markers
US8247401B2 (en) 2007-10-31 2012-08-21 Merck Sharp & Dohme Corp. P2X3 receptor antagonists for treatment of pain
NZ586418A (en) 2007-12-19 2012-09-28 Cancer Rec Tech Ltd Pyrido[2,3-b]pyrazine-8-substituted compounds and their use
KR101608096B1 (ko) 2008-01-23 2016-03-31 브리스톨-마이어스 스큅 컴퍼니 ４-피리디논 화합물 및 암을 위한 그의 용도
WO2009124137A2 (en) 2008-04-01 2009-10-08 Mount Sinai School Of Medicine Of New York University Method of suppressing gene transcription through histone lysine methylation
US20100113415A1 (en) 2008-05-29 2010-05-06 Rajapakse Hemaka A Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer
WO2010017355A2 (en) * 2008-08-08 2010-02-11 New York Blood Center Small molecule inhibitors of retroviral assembly and maturation
FR2934995B1 (fr) 2008-08-14 2010-08-27 Sanofi Aventis Composes d'azetidines polysubstitues, leur preparation et leur application en therapeutique
CA2738583A1 (en) 2008-10-01 2010-04-08 Ludwig Institute For Cancer Research Methods for the treatment of cancer
US20120065247A1 (en) 2009-03-27 2012-03-15 Discoverybiomed, Inc. Modulating ires-mediated translation
US20110021362A1 (en) 2009-07-20 2011-01-27 Constellation Pharmaceuticals Agents for stimulating activity of methyl modifying enzymes and methods of use thereof
US8329149B2 (en) 2009-12-30 2012-12-11 Avon Products, Inc. Topical lightening composition and uses thereof
CN102970869B (zh) 2010-05-07 2014-07-16 葛兰素史密斯克莱有限责任公司 吲哚
JP5889875B2 (ja) 2010-05-07 2016-03-22 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ アザインダゾール
EP2566328B1 (en) 2010-05-07 2015-03-04 GlaxoSmithKline LLC Indazoles
BR112013005806B1 (pt) 2010-09-10 2022-05-10 Epizyme, Inc Métodos para detectar se um indivíduo é um candidato para o tratamento com ou responsivo a um inibidor de ezh2 e usos terapêuticos do dito inibidor de ezh2
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
WO2012068589A2 (en) 2010-11-19 2012-05-24 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
WO2012075080A1 (en) 2010-12-01 2012-06-07 Glaxosmithkline Llc Indoles
EP2646454B1 (en) 2010-12-03 2015-07-08 Epizyme, Inc. 7-deazapurine modulators of histone methyltransferase, and methods of use thereof
WO2012118812A2 (en) 2011-02-28 2012-09-07 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
JO3438B1 (ar) * 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
WO2013003635A1 (en) 2011-06-28 2013-01-03 Stoplift, Inc. Image processing to prevent access to private information
US9562041B2 (en) 2012-05-16 2017-02-07 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
US9006242B2 (en) 2012-10-15 2015-04-14 Epizyme, Inc. Substituted benzene compounds

Also Published As

Publication number Publication date
RU2629118C2 (ru) 2017-08-24
US20160332969A1 (en) 2016-11-17
TW201305107A (zh) 2013-02-01
KR101975613B1 (ko) 2019-05-07
HK1202534A1 (en) 2015-10-02
IL228746B (en) 2019-08-29
PT2697198T (pt) 2016-09-13
EP3470396A1 (en) 2019-04-17
US9376422B2 (en) 2016-06-28
RU2017126990A (ru) 2019-02-01
JP2014513084A (ja) 2014-05-29
WO2012142513A1 (en) 2012-10-18
IL228746A0 (en) 2013-12-31
EP2697198A1 (en) 2014-02-19
RU2013150510A (ru) 2015-05-20
CN104066718A (zh) 2014-09-24
RU2017126990A3 (es) 2020-10-30
PL2697198T3 (pl) 2016-12-30
CA2832846A1 (en) 2012-10-18
MX2013011922A (es) 2014-04-10
MX344530B (es) 2016-12-19
AU2017218920A1 (en) 2017-09-07
EP3165520B1 (en) 2018-08-15
HUE030722T2 (en) 2017-05-29
CA2832846C (en) 2022-04-19
AU2012242604B2 (en) 2017-05-25
CN104066718B (zh) 2017-08-29
BR112013026308A2 (pt) 2022-07-19
KR20140034787A (ko) 2014-03-20
BR112013026308B1 (pt) 2024-01-02
ES2590489T3 (es) 2016-11-22
US20140142083A1 (en) 2014-05-22
TWI598336B (zh) 2017-09-11
EP2697198B1 (en) 2016-06-08
EP3165520A1 (en) 2017-05-10
AU2012242604A1 (en) 2013-10-24
DK2697198T3 (en) 2016-09-19
TW201733984A (zh) 2017-10-01

Similar Documents

Publication Publication Date Title
AR086839A1 (es) Derivados de piridin-2-ona con actividad inhibitoria de ezh2
AR086008A1 (es) Compuestos de benceno sustituidos con arilo o heteroarilo
AR126406A2 (es) Compuestos de tetrazolinona y su uso
AR087760A1 (es) Heterociclilaminas como inhibidores de pi3k
AR101175A1 (es) Imidazopiridinas e imidazopirazinas como inhibidores de lsd1
AR094410A1 (es) Compuestos terapéuticos
AR101600A1 (es) COMPUESTOS DE SPIRO[3H-INDOL-3,2-PIRROLIDIN]-2(1H)-ONA Y DERIVADOS COMO INHIBIDORES DE MDM2-p53
RU2014114466A (ru) ИНДАЗОЛ-3-КАРБОКСАМИДЫ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ СИГНАЛЬНОГО ПУТИ WNT/β-КАТЕНИНА
AR085283A1 (es) Antagonistas de hepcidina a base de sulfonaminoquinolina
AR092108A1 (es) Piridazina 1,4 disustituida, analogos de la misma y metodos para tratar las enfermedades relacionadas con deficiencia del smn
AR080057A1 (es) Piridinas disustituidas como anticancerigenos
AR076066A1 (es) Inhibidores de la tirosina-quinasa de bruton
AR083933A1 (es) Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
JP2016522172A5 (es)
AR081653A1 (es) Inhibidores del virus de la hepatitis c
AR105845A1 (es) Compuestos de heteroarilo bicíclicos fusionados como moduladores de la función irak4
AR094816A2 (es) Compuestos antivirales
AR089776A1 (es) 5,8-dihidro-6h-pirazolo[3,4-h]quinazolinas como inhibidores de igf-1r/ir
AR082850A1 (es) Aminopirazoloquinazolinas
PE20170127A1 (es) Indazol-3-carboxamidas 5-sustituidas y preparacion y uso de las mismas
AR081848A1 (es) Inhibidores de la proteina ns5a del vhc
AR051342A1 (es) Derivados de purina, purinona, deazapurina y deazapurinona como inhibidores de la actividad de la protein quinasa; metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en la elaboracion de un medicamento para el tratamiento de enfermedades mediadas por la protein quina
AR059338A1 (es) N-fenilbenzotriazolilo como inhibidores de c-kit
AR084706A1 (es) Derivados sustituidos de imidazoquinolinas como inhibidores de quinasa y proceso para su preparacion
ES2620668T3 (es) Derivados de amidas y sulfonamidas amido espirocíclicas

Legal Events

Date Code Title Description
FB Suspension of granting procedure